Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


CONTINUING MEDICAL EDUCATION INFORMATION

Release Date: March 7, 2014
Last Reviewed: March 7, 2014
Expiration Date: March 7, 2015
Time to Complete Activity: 15 minutes

TARGET AUDIENCE

This activity has been designed to meet the educational needs of physicians with an interest in Diabetes & Endocrinology, as well as other health care professionals.

STATEMENT OF NEED

This activity will supply up-to-date news information to practicing clinicians which can be integrated into practice and aims to increase professional competency.

EDUCATIONAL OBJECTIVES

Upon proper completion of this activity, participants should be better able to:

  • Summarize the significance of the study in the context of clinical care.

DISCLOSURES

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Neither Paradigm Medical Communications, LLC, staff nor HealthDay’s medical writer have financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

In STEMI, Hyperglycemia Tied to Larger Myocardial Area-at-Risk
Exenatide treatment correlates with increased salvage index, independent of glucose level

FRIDAY, March 7, 2014 (HealthDay News) -- For patients with ST-segment elevation myocardial infarction (STEMI), hyperglycemia is associated with larger area-at-risk and infarct size, and the effect of exenatide treatment is independent of glucose levels, according to a study published online Feb. 28 in Diabetes.

Jacob Lønborg, M.D., Ph.D., from Copenhagen University Hospital in Denmark, and colleagues examined the correlation between hyperglycemia and infarct size, myocardial salvage, and area-at-risk in a cohort of 210 patients with STEMI. Participants were randomized to receive intravenous exenatide or placebo before percutaneous coronary intervention, and the interaction between exenatide and hyperglycemia was assessed.

The researchers found that larger area-at-risk and infarct size were seen for patients with hyperglycemia versus those with normoglycemia, but no difference was seen between the groups in the salvage index and infarct size after adjustment for area-at-risk. For patients with hyperglycemia and those with normoglycemia, exenatide treatment correlated with increased salvage index.

"Thus, we conclude that the association between hyperglycemia upon admission and infarct size in STEMI patients is a consequence of a larger myocardial area-at-risk but not on a reduction in myocardial salvage. Also, cardioprotection by exenatide treatment is independent of admission glucose levels," the authors write. "Hyperglycemia does not influence the effect of the reperfusion treatment but rather represents a surrogate marker for the severity of myocardium at risk and injury."

One author disclosed being a shareholder in CellAegis; several authors disclosed financial ties to Eli Lilly.

Abstract
Full Text (subscription or payment may be required)


To earn CME credits for reading this article, click here

Copyright © 2014 HealthDay. All rights reserved.

September 19, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

CDC: Almost Everyone Needs a Flu Shot

Strategies Can Help Docs Lower Their Tax Burden

Insulin Rx Tied to Increased Major Adverse CV Events in DM

EASD: Insulin Pumps Reduce Mortality, Fatal CVD Risk

ER Timeliness to Be Improved but Some Measures May Backfire

High Mortality, Costs With C. difficile After Spine Surgery